LB Pharmaceuticals Inc Common Stock (LBRX)
US — Healthcare Sector
Automate Your Wheel Strategy on LBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including LBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LBRX
- Rev/Share 0.0
- Book/Share -26.7136
- PB -0.5469
- Debt/Equity -0.0392
- CurrentRatio 3.5614
- ROIC -2.502
- MktCap 327892069.0
- FreeCF/Share -15.2056
- PFCF -6.0923
- PE -0.8195
- Debt/Assets 0.1104
- DivYield 0
- ROE 0.9781
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LBRX | Leerink Partners | -- | Outperform | -- | $34 | Oct. 6, 2025 |
| Initiation | LBRX | Piper Sandler | -- | Overweight | -- | $78 | Oct. 6, 2025 |
| Initiation | LBRX | Stifel | -- | Buy | -- | $27 | Oct. 6, 2025 |
News
About LB Pharmaceuticals Inc Common Stock (LBRX)
- IPO Date 2025-09-11
- Website https://lbpharma.us
- Industry Biotechnology
- CEO Heather D. Turner
- Employees 16
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.